Medical - Instruments & Supplies
Compare Stocks
5 / 10Stock Comparison
MLSS vs XRAY vs HSIC vs NVST vs ALGN
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Instruments & Supplies
Medical - Distribution
Medical - Equipment & Services
Medical - Devices
MLSS vs XRAY vs HSIC vs NVST vs ALGN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Instruments & Supplies | Medical - Instruments & Supplies | Medical - Distribution | Medical - Equipment & Services | Medical - Devices |
| Market Cap | $37M | $2.20B | $8.09B | $4.04B | $12.06B |
| Revenue (TTM) | $9M | $3.68B | $13.18B | $2.81B | $4.10B |
| Net Income (TTM) | $-7M | $-628M | $398M | $68M | $430M |
| Gross Margin | 72.8% | 48.9% | 29.1% | 55.1% | 67.7% |
| Operating Margin | -77.0% | 4.1% | 5.8% | 9.0% | 14.4% |
| Forward P/E | — | 7.7x | 13.3x | 17.2x | 14.9x |
| Total Debt | $349K | $2.47B | $3.69B | $1.71B | $114M |
| Cash & Equiv. | $3M | $326M | $156M | $1.21B | $1.08B |
MLSS vs XRAY vs HSIC vs NVST vs ALGN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Milestone Scientifi… (MLSS) | 100 | 25.5 | -74.5% |
| DENTSPLY SIRONA Inc. (XRAY) | 100 | 23.6 | -76.4% |
| Henry Schein, Inc. (HSIC) | 100 | 116.1 | +16.1% |
| Envista Holdings Co… (NVST) | 100 | 114.9 | +14.9% |
| Align Technology, I… (ALGN) | 100 | 68.6 | -31.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MLSS vs XRAY vs HSIC vs NVST vs ALGN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
MLSS is the clearest fit if your priority is sleep-well-at-night and defensive.
- Lower volatility, beta 0.94, Low D/E 6.0%, current ratio 2.48x
- Beta 0.94, current ratio 2.48x
XRAY is the clearest fit if your priority is dividends.
- 5.9% yield; 23-year raise streak; the other 4 pay no meaningful dividend
HSIC has the current edge in this matchup, primarily because of its strength in income & stability and long-term compounding.
- Dividend streak 1 yrs, beta 0.73
- 5.3% 10Y total return vs ALGN's 122.8%
- PEG 4.21 vs NVST's 11.53
- Lower P/E (13.3x vs 14.9x)
NVST is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 8.3%, EPS growth 104.3%, 3Y rev CAGR 1.9%
- 8.3% revenue growth vs MLSS's -12.2%
- +44.2% vs MLSS's -48.5%
ALGN ranks third and is worth considering specifically for quality and efficiency.
- 10.5% margin vs MLSS's -76.8%
- 6.9% ROA vs MLSS's -86.6%, ROIC 15.4% vs -121.3%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 8.3% revenue growth vs MLSS's -12.2% | |
| Value | Lower P/E (13.3x vs 14.9x) | |
| Quality / Margins | 10.5% margin vs MLSS's -76.8% | |
| Stability / Safety | Beta 0.73 vs XRAY's 1.78, lower leverage | |
| Dividends | 5.9% yield; 23-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +44.2% vs MLSS's -48.5% | |
| Efficiency (ROA) | 6.9% ROA vs MLSS's -86.6%, ROIC 15.4% vs -121.3% |
MLSS vs XRAY vs HSIC vs NVST vs ALGN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
MLSS vs XRAY vs HSIC vs NVST vs ALGN — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ALGN leads in 2 of 6 categories
XRAY leads 2 • HSIC leads 1 • MLSS leads 0 • NVST leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ALGN leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HSIC is the larger business by revenue, generating $13.2B annually — 1451.5x MLSS's $9M. ALGN is the more profitable business, keeping 10.5% of every revenue dollar as net income compared to MLSS's -76.8%. On growth, MLSS holds the edge at +25.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $9M | $3.7B | $13.2B | $2.8B | $4.1B |
| EBITDAEarnings before interest/tax | -$7M | $424M | $1.1B | $342M | $790M |
| Net IncomeAfter-tax profit | -$7M | -$628M | $398M | $68M | $430M |
| Free Cash FlowCash after capex | -$5M | $104M | $561M | $220M | $717M |
| Gross MarginGross profit ÷ Revenue | +72.8% | +48.9% | +29.1% | +55.1% | +67.7% |
| Operating MarginEBIT ÷ Revenue | -77.0% | +4.1% | +5.8% | +9.0% | +14.4% |
| Net MarginNet income ÷ Revenue | -76.8% | -17.1% | +3.0% | +2.4% | +10.5% |
| FCF MarginFCF ÷ Revenue | -57.9% | +2.8% | +4.3% | +7.8% | +17.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +25.3% | +0.1% | +7.7% | +14.4% | +6.2% |
| EPS Growth (YoY)Latest quarter vs prior year | — | -150.0% | +14.9% | +130.0% | +23.6% |
Valuation Metrics
XRAY leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 21.6x trailing earnings, HSIC trades at a 75% valuation discount to NVST's 86.7x P/E. Adjusting for growth (PEG ratio), HSIC offers better value at 6.84x vs NVST's 58.08x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $37M | $2.2B | $8.1B | $4.0B | $12.1B |
| Enterprise ValueMkt cap + debt − cash | $34M | $4.3B | $11.6B | $4.5B | $11.1B |
| Trailing P/EPrice ÷ TTM EPS | -7.94x | -3.65x | 21.56x | 86.73x | 29.80x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 7.68x | 13.26x | 17.21x | 14.85x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 6.84x | 58.08x | — |
| EV / EBITDAEnterprise value multiple | — | 7.18x | 10.87x | 13.28x | 13.92x |
| Price / SalesMarket cap ÷ Revenue | 4.27x | 0.60x | 0.61x | 1.49x | 2.99x |
| Price / BookPrice ÷ Book value/share | 6.42x | 1.63x | 1.79x | 1.32x | 3.02x |
| Price / FCFMarket cap ÷ FCF | — | 21.11x | 14.12x | 17.54x | 24.57x |
Profitability & Efficiency
ALGN leads this category, winning 8 of 9 comparable metrics.
Profitability & Efficiency
ALGN delivers a 10.7% return on equity — every $100 of shareholder capital generates $11 in annual profit, vs $-2 for MLSS. ALGN carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to XRAY's 1.84x. On the Piotroski fundamental quality scale (0–9), NVST scores 7/9 vs HSIC's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -2.1% | -41.2% | +8.2% | +2.2% | +10.7% |
| ROA (TTM)Return on assets | -86.6% | -11.2% | +3.6% | +1.2% | +6.9% |
| ROICReturn on invested capital | -121.3% | +5.1% | +7.1% | +4.8% | +15.4% |
| ROCEReturn on capital employed | -94.2% | +6.1% | +9.8% | +4.9% | +14.5% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 6 | 4 | 7 | 7 |
| Debt / EquityFinancial leverage | 0.06x | 1.84x | 0.77x | 0.55x | 0.03x |
| Net DebtTotal debt minus cash | -$3M | $2.1B | $3.5B | $496M | -$965M |
| Cash & Equiv.Liquid assets | $3M | $326M | $156M | $1.2B | $1.1B |
| Total DebtShort + long-term debt | $349,054 | $2.5B | $3.7B | $1.7B | $114M |
| Interest CoverageEBIT ÷ Interest expense | — | -5.12x | 4.59x | 12.76x | 389.13x |
Total Returns (Dividends Reinvested)
HSIC leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HSIC five years ago would be worth $8,746 today (with dividends reinvested), compared to $1,914 for MLSS. Over the past 12 months, NVST leads with a +44.2% total return vs MLSS's -48.5%. The 3-year compound annual growth rate (CAGR) favors HSIC at -4.0% vs XRAY's -32.6% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +61.7% | -2.8% | -8.2% | +12.0% | +7.9% |
| 1-Year ReturnPast 12 months | -48.5% | -16.4% | +5.9% | +44.2% | -2.2% |
| 3-Year ReturnCumulative with dividends | -37.5% | -69.4% | -11.7% | -30.3% | -45.0% |
| 5-Year ReturnCumulative with dividends | -80.9% | -80.1% | -12.5% | -46.6% | -71.9% |
| 10-Year ReturnCumulative with dividends | -79.9% | -74.5% | +5.3% | -13.1% | +122.8% |
| CAGR (3Y)Annualised 3-year return | -14.5% | -32.6% | -4.0% | -11.3% | -18.1% |
Risk & Volatility
Evenly matched — HSIC and ALGN each lead in 1 of 2 comparable metrics.
Risk & Volatility
HSIC is the less volatile stock with a 0.73 beta — it tends to amplify market swings less than XRAY's 1.78 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALGN currently trades 80.8% from its 52-week high vs MLSS's 44.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.94x | 1.78x | 0.73x | 1.65x | 1.66x |
| 52-Week HighHighest price in past year | $1.05 | $17.18 | $89.29 | $30.42 | $208.31 |
| 52-Week LowLowest price in past year | $0.22 | $9.85 | $61.95 | $16.33 | $122.00 |
| % of 52W HighCurrent price vs 52-week peak | +44.7% | +63.8% | +79.0% | +79.8% | +80.8% |
| RSI (14)Momentum oscillator 0–100 | 72.6 | 39.2 | 39.1 | 55.1 | 44.6 |
| Avg Volume (50D)Average daily shares traded | 2.3M | 4.2M | 1.2M | 2.4M | 1.1M |
Analyst Outlook
XRAY leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: XRAY as "Hold", HSIC as "Hold", NVST as "Hold", ALGN as "Buy". Consensus price targets imply 22.6% upside for HSIC (target: $86) vs 11.2% for NVST (target: $27). XRAY is the only dividend payer here at 5.86% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold | Hold | Hold | Buy |
| Price TargetConsensus 12-month target | — | $13.40 | $86.43 | $27.00 | $203.60 |
| # AnalystsCovering analysts | — | 31 | 32 | 19 | 33 |
| Dividend YieldAnnual dividend ÷ price | — | +5.9% | — | — | — |
| Dividend StreakConsecutive years of raises | — | 23 | 1 | — | — |
| Dividend / ShareAnnual DPS | — | $0.64 | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +10.5% | +4.1% | +3.9% |
ALGN leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). XRAY leads in 2 (Valuation Metrics, Analyst Outlook). 1 tied.
MLSS vs XRAY vs HSIC vs NVST vs ALGN: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is MLSS or XRAY or HSIC or NVST or ALGN a better buy right now?
For growth investors, Envista Holdings Corp (NVST) is the stronger pick with 8.
3% revenue growth year-over-year, versus -12. 2% for Milestone Scientific Inc. (MLSS). Henry Schein, Inc. (HSIC) offers the better valuation at 21. 6x trailing P/E (13. 3x forward), making it the more compelling value choice. Analysts rate Align Technology, Inc. (ALGN) a "Buy" — based on 33 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — MLSS or XRAY or HSIC or NVST or ALGN?
On trailing P/E, Henry Schein, Inc.
(HSIC) is the cheapest at 21. 6x versus Envista Holdings Corp at 86. 7x. On forward P/E, DENTSPLY SIRONA Inc. is actually cheaper at 7. 7x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Henry Schein, Inc. wins at 4. 21x versus Envista Holdings Corp's 11. 53x.
03Which is the better long-term investment — MLSS or XRAY or HSIC or NVST or ALGN?
Over the past 5 years, Henry Schein, Inc.
(HSIC) delivered a total return of -12. 5%, compared to -80. 9% for Milestone Scientific Inc. (MLSS). Over 10 years, the gap is even starker: ALGN returned +122. 8% versus MLSS's -79. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — MLSS or XRAY or HSIC or NVST or ALGN?
By beta (market sensitivity over 5 years), Henry Schein, Inc.
(HSIC) is the lower-risk stock at 0. 73β versus DENTSPLY SIRONA Inc. 's 1. 78β — meaning XRAY is approximately 144% more volatile than HSIC relative to the S&P 500. On balance sheet safety, Align Technology, Inc. (ALGN) carries a lower debt/equity ratio of 3% versus 184% for DENTSPLY SIRONA Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — MLSS or XRAY or HSIC or NVST or ALGN?
By revenue growth (latest reported year), Envista Holdings Corp (NVST) is pulling ahead at 8.
3% versus -12. 2% for Milestone Scientific Inc. (MLSS). On earnings-per-share growth, the picture is similar: Envista Holdings Corp grew EPS 104. 3% year-over-year, compared to 0. 5% for Align Technology, Inc.. Over a 3-year CAGR, ALGN leads at 2. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — MLSS or XRAY or HSIC or NVST or ALGN?
Align Technology, Inc.
(ALGN) is the more profitable company, earning 10. 2% net margin versus -54. 6% for Milestone Scientific Inc. — meaning it keeps 10. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALGN leads at 15. 3% versus -78. 3% for MLSS. At the gross margin level — before operating expenses — MLSS leads at 74. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is MLSS or XRAY or HSIC or NVST or ALGN more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Henry Schein, Inc. (HSIC) is the more undervalued stock at a PEG of 4. 21x versus Envista Holdings Corp's 11. 53x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, DENTSPLY SIRONA Inc. (XRAY) trades at 7. 7x forward P/E versus 17. 2x for Envista Holdings Corp — 9. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HSIC: 22. 6% to $86. 43.
08Which pays a better dividend — MLSS or XRAY or HSIC or NVST or ALGN?
In this comparison, XRAY (5.
9% yield) pays a dividend. MLSS, HSIC, NVST, ALGN do not pay a meaningful dividend and should not be held primarily for income.
09Is MLSS or XRAY or HSIC or NVST or ALGN better for a retirement portfolio?
For long-horizon retirement investors, Henry Schein, Inc.
(HSIC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 73)). Envista Holdings Corp (NVST) carries a higher beta of 1. 65 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HSIC: +5. 3%, NVST: -13. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between MLSS and XRAY and HSIC and NVST and ALGN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: MLSS is a small-cap quality compounder stock; XRAY is a small-cap income-oriented stock; HSIC is a small-cap quality compounder stock; NVST is a small-cap quality compounder stock; ALGN is a mid-cap quality compounder stock. XRAY pays a dividend while MLSS, HSIC, NVST, ALGN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.